News | Coronavirus (COVID-19) | April 08, 2020

No Evidence Supporting Discontinuing RAAS Inhibitors in COVID-19 Patients

ACE and ARBs provide benefit to cardiac patients and harm to COVID-19 patients remains unproven

ACE and ARBs provide benefit to cardiac patients and harm to COVID-19 patients remains unproven, NEJM

April 8, 2020 — There has been debate in the past month or so during the novel coronavirus (COVID-19) pandemic whether the renin-angiotensin-aldosterone system (RAAS) inhibitors, such as angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), should be stopped in COVID-19 patients. An article in the New England Journal of Medicine (NEJM) suggests these medications provide known benefits to patients who need them, while potential harms remain unproven.[1]

RAAS experts have provided a useful special report summarizing the evidence about the use of ACE inhibitors and ARBs, in patients with COVID-19. The data may provide context for the recommendations from several professional groups. The article suggests treatment with RAAS inhibitors should not be changed out of concerns that they might increase or decrease risk in patients with COVID-19, said Harlan M. Krumholz, M.D., director of the Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, who reviewed the article in NEJM Journal Watch.

SARS-CoV-2, the virus that causes COVID-19, enters cells by binding to ACE2 as a receptor. ACE2 counters RAAS activation, primarily by degrading angiotensin II to angiotensin-(1–7), reducing angiotensin II's effects on vasoconstriction, sodium retention, and fibrosis. Some preclinical studies indicated that RAAS inhibitors may increase the expression of ACE2, raising concerns that these medications could increase susceptibility to infection. Nevertheless, whether ACE inhibitors or ARBs harm patients with COVID-19 or, even, are protective against the disease remains unknown. 

However, withdrawing these therapies in patients for whom they are indicated could be expected to increase risks from patients' underlying conditions or from COVID-19 complications. The authors strongly endorse continuing RAAS inhibitors until better evidence suggests otherwise.

 

Related ACE and ARB COVID-19 Content:

COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues

AHA, ACC, HRS Caution Use of COVID-19 Therapies Hydroxychloroquine and Azithromycin in Cardiac Patients

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D.

Reference:

1. Vaduganathan M et al. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020 Mar 30; [e-pub]. https://doi.org/10.1056/NEJMsr2005760.

 


Related Content

News | Cardiovascular Clinical Studies

January 26, 2023 — A newly-released study extends the understanding of how acquired mutations in blood cells act as a ...

Home January 26, 2023
Home
News | Cardiovascular Clinical Studies

January 24, 2023 — Four cardiology organizations have joined forces in a call to action to reinvent randomized clinical ...

Home January 24, 2023
Home
News | Cardiovascular Clinical Studies

January 11, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies ...

Home January 11, 2023
Home
News | Cardiovascular Clinical Studies

January 3, 2023 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac ...

Home January 03, 2023
Home
News | Cardiovascular Clinical Studies

December 30, 2022 — The Cardiovascular Research Foundation (CRF) recently announced that Alexandra Popma, MD, has joined ...

Home December 30, 2022
Home
News | Cardiovascular Clinical Studies

December 28 2022 — Abiomed announces the United States Food and Drug Administration (FDA) has approved the version of ...

Home December 28, 2022
Home
News | Cardiovascular Clinical Studies

December 27, 2022 — A groundbreaking new clinical trial to determine the effectiveness of a new treatment for patients ...

Home December 27, 2022
Home
News | Cardiovascular Clinical Studies

December 21, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting ...

Home December 21, 2022
Home
News | Cardiovascular Clinical Studies

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without ...

Home December 13, 2022
Home
News | Cardiovascular Clinical Studies

December 9, 2022 — BioSig Technologies, Inc. an advanced digital signal processing technology company delivering ...

Home December 09, 2022
Home
Subscribe Now